Association between opioid prescription profiles and adverse health outcomes in opioid users referred for sleep disorder assessment: a secondary analysis of health administrative data

T. Kendzerska, A. Malhotra, A. Gershon, M. Povitz, D. McIsaac, S. Aaron, G. Bryson, R. Talarico, Michael Godbout, P. Tanuseputro, F. Chung
{"title":"Association between opioid prescription profiles and adverse health outcomes in opioid users referred for sleep disorder assessment: a secondary analysis of health administrative data","authors":"T. Kendzerska, A. Malhotra, A. Gershon, M. Povitz, D. McIsaac, S. Aaron, G. Bryson, R. Talarico, Michael Godbout, P. Tanuseputro, F. Chung","doi":"10.3389/frsle.2023.1161857","DOIUrl":null,"url":null,"abstract":"Information is needed to guide safe opioid prescribing in adults referred for a sleep disorder assessment. Previous studies have shown that individuals referred for a sleep disorder assessment have a higher likelihood of long-acting opioids and higher opioid dosages prescription than the general population, suggesting that these individuals are more at risk for opioid-related adverse health consequences.We included all adults who underwent a diagnostic sleep study (index date) in Ontario, Canada, between 2013 and 2016 (n = 300,663) and filled an opioid prescription overlapping the index date (n = 15,713). Through provincial health administrative databases, individuals were followed over time to assess the association between opioid use characteristics and 1-year all-cause mortality, hospitalizations and emergency department (ED) visits, and opioid-related hospitalizations and ED visits within extended follow-up to 2018.Controlling for covariates, chronic opioid use (vs. not) was significantly associated with increased hazards of all-cause mortality [adjusted hazard ratio(aHR): 1.84; 95% confidence interval (CI): 1.12–3.02], hospitalization (aHR: 1.14; 95% CI: 1.02–1.28) and ED visit (aHR: 1.09; 95% CI: 1.01–1.17). A higher opioid dosage [morphine equivalent daily dose (MED) >90 vs. ≤ 90 mg/day] was significantly associated with increased hazards of all-cause or opioid-related hospitalization (aHR: 1.13; 95% CI: 1.02–1.26 and aHR: 2.27; 95% CI: 1.53–3.37, respectively). Morphine or hydromorphone prescription (vs. oxycodone) was significantly associated with an increased hazard of all-cause hospitalization (aHR: 1.30; 1.07–1.59 and aHR: 1.43; 95% CI: 1.20–1.70, respectively). Hydromorphone or fentanyl prescription (vs. oxycodone) was significantly associated with an increased hazard of opioid-related ED visit and/or hospitalization (aHR: 2.28, 95% CI: 1.16–4.47 and aHR: 2.47, 95% CI: 1.16–5.26, respectively).Findings from this retrospective study may inform the safe prescribing of opioids in adults referred for a sleep disorder assessment.","PeriodicalId":73106,"journal":{"name":"Frontiers in sleep","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in sleep","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frsle.2023.1161857","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Information is needed to guide safe opioid prescribing in adults referred for a sleep disorder assessment. Previous studies have shown that individuals referred for a sleep disorder assessment have a higher likelihood of long-acting opioids and higher opioid dosages prescription than the general population, suggesting that these individuals are more at risk for opioid-related adverse health consequences.We included all adults who underwent a diagnostic sleep study (index date) in Ontario, Canada, between 2013 and 2016 (n = 300,663) and filled an opioid prescription overlapping the index date (n = 15,713). Through provincial health administrative databases, individuals were followed over time to assess the association between opioid use characteristics and 1-year all-cause mortality, hospitalizations and emergency department (ED) visits, and opioid-related hospitalizations and ED visits within extended follow-up to 2018.Controlling for covariates, chronic opioid use (vs. not) was significantly associated with increased hazards of all-cause mortality [adjusted hazard ratio(aHR): 1.84; 95% confidence interval (CI): 1.12–3.02], hospitalization (aHR: 1.14; 95% CI: 1.02–1.28) and ED visit (aHR: 1.09; 95% CI: 1.01–1.17). A higher opioid dosage [morphine equivalent daily dose (MED) >90 vs. ≤ 90 mg/day] was significantly associated with increased hazards of all-cause or opioid-related hospitalization (aHR: 1.13; 95% CI: 1.02–1.26 and aHR: 2.27; 95% CI: 1.53–3.37, respectively). Morphine or hydromorphone prescription (vs. oxycodone) was significantly associated with an increased hazard of all-cause hospitalization (aHR: 1.30; 1.07–1.59 and aHR: 1.43; 95% CI: 1.20–1.70, respectively). Hydromorphone or fentanyl prescription (vs. oxycodone) was significantly associated with an increased hazard of opioid-related ED visit and/or hospitalization (aHR: 2.28, 95% CI: 1.16–4.47 and aHR: 2.47, 95% CI: 1.16–5.26, respectively).Findings from this retrospective study may inform the safe prescribing of opioids in adults referred for a sleep disorder assessment.
转介进行睡眠障碍评估的阿片类药物使用者阿片类药物处方概况与不良健康结果之间的关联:对卫生行政数据的二次分析
需要信息来指导成人进行睡眠障碍评估时的阿片类药物安全处方。先前的研究表明,与一般人群相比,接受睡眠障碍评估的个体更有可能服用长效阿片类药物和更高的阿片类药物剂量,这表明这些个体更有可能出现与阿片类药物相关的不良健康后果。我们纳入了2013年至2016年在加拿大安大略省接受诊断性睡眠研究(索引日期)的所有成年人(n = 300,663),并填写了与索引日期重叠的阿片类药物处方(n = 15,713)。通过省级卫生行政数据库,对个体进行了一段时间的随访,以评估阿片类药物使用特征与1年全因死亡率、住院和急诊(ED)就诊以及阿片类药物相关住院和ED就诊之间的关系。控制协变量,慢性阿片类药物使用(与不使用)与全因死亡率风险增加显著相关[校正风险比(aHR): 1.84;95%可信区间(CI): 1.12-3.02],住院率(aHR: 1.14;95% CI: 1.02-1.28)和ED就诊(aHR: 1.09;95% ci: 1.01-1.17)。较高的阿片类药物剂量[吗啡当量日剂量(MED) bbb90 vs.≤90 mg/天]与全因或阿片类药物相关住院风险增加显著相关(aHR: 1.13;95% CI: 1.02-1.26, aHR: 2.27;95% CI分别为1.53-3.37)。吗啡或氢吗啡酮处方(相对于羟考酮)与全因住院风险增加显著相关(aHR: 1.30;1.07-1.59, aHR为1.43;95% CI分别为1.20-1.70)。氢吗啡酮或芬太尼处方(与羟考酮相比)与阿片类药物相关ED就诊和/或住院的风险增加显著相关(aHR: 2.28, 95% CI: 1.16-4.47, aHR: 2.47, 95% CI: 1.16-5.26)。这项回顾性研究的发现可能会为接受睡眠障碍评估的成人开具阿片类药物的安全处方提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信